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Abstract
Functional dyspepsia is a prevalent functional gastrointestinal disorder that can
significantly erode the quality of life of sufferers and places a major cost burden
on healthcare services. In this article, we review the recent literature, selecting
the information we consider relevant since it has changed our clinical
management of patients with functional dyspepsia.
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Introduction
About 20% of the population has chronic symptoms that can be 
attributed to disorders of gastroduodenal motility and function, 
which the recently published Rome IV criteria have classified 
into four categories: functional dyspepsia (FD), belching dis-
orders, chronic nausea and vomiting disorders, and rumination 
syndrome1. This diagnostic classification is largely unchanged 
from previous iterations with only minor changes made to the 
definition (Table 1).
Definition
FD is a functional gastrointestinal (GI) disorder characterized by 
one or more of the following symptoms: postprandial fullness, 
early satiation, epigastric pain, and epigastric burning1. Nausea and 
vomiting are no longer considered cardinal FD symptoms and have 
been moved into separate categories of functional nausea and vom-
iting disorders2. Based on factor analyses of digestive symptoms 
in the general population and FD patients, the Rome Committee 
further divided patients with FD into two subgroups: postprandial 
distress syndrome (PDS), which is characterized by meal-induced 
symptoms, and epigastric pain syndrome (EPS), which refers to 
epigastric pain or epigastric burning that does not occur exclusively 
postprandially and can even be improved by meal ingestion2. In 
clinical practice, PDS is more prevalent than EPS1; however, the 
overlap between PDS and EPS patients has been reported to be as 
high as 50%1,2. Therefore, the clinical utility of this subdivision has 
been questioned1, even though it seems reasonable to distinguish 
between patients with symptoms induced by food intake (that is, 
PDS, previously called “dysmotility-like”) and those in whom 
symptoms are largely independent of GI function (that is, EPS, 
previously called “ulcer-like”). Moreover, a recent study has 
demonstrated that the overlap can be reduced by a more rigorous 
linking of postprandially occurring symptoms to PDS, regardless 
of their qualitative nature3,4. This means that epigastric pain or 
burning, if postprandial, can also be present in PDS3,4. One change 
made by Rome IV is to limit the diagnosis of FD to patients with 
“bothersome symptoms… severe enough to impact on usual 
activities” occurring with a minimal frequency of 3 days per week1. 
This is necessary to distinguish those with clinically relevant 
disease from healthy subjects with occasional, relatively mild 
symptoms that can be considered part of normal daily life. FD 
patients who meet these diagnostic criteria have reduced quality 
of life and incur significant direct costs through medical expenses 
and indirectly through loss of productivity1.
Pathophysiology
The causes of FD are not completely understood; however, 
several mechanisms appear to be involved. These include altered 
gastric emptying, impaired gastric accommodation, gastric and 
duodenal hypersensitivity, and previous GI infections1. Addition-
ally, the presence of psychiatric disease and psychosocial stress 
factors has a role in FD aetiology and severity1. Delayed gastric 
emptying has been reported in up to 35% of patients with FD, 
whereas rapid gastric emptying, even if less studied, is probably 
Table 1. Rome IV criteria for functional dyspepsia.
Diagnostic Rome IV criteria for functional dyspepsia (changes from Rome III criteria appear in bold) 
1. One or more of the following: a. bothersome postprandial fullness; b. bothersome early satiation; c. bothersome epigastric 
pain; d. bothersome epigastric burning AND 2. No evidence of structural disease (including at upper endoscopy) that is likely to 
explain the symptoms 
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis
Diagnostic criteria for postprandial distress syndrome 
Must include one or both of the following at least 3 days per week:
1. Bothersome postprandial fullness (that is, severe enough to impact on usual activities)
2. Bothersome early satiation (that is, severe enough to prevent finishing a regular-sized meal)
Supportive criteria 
1. Postprandial epigastric pain or burning, epigastric bloating, excessive belching, and nausea can also be present; 2. vomiting 
warrants consideration of another disorder; 3. heartburn is not a dyspeptic symptom but may often co-exist; 4. symptoms 
that are relieved by evacuation of faeces or gas should generally not be considered part of dyspepsia; 5. other individual 
digestive symptoms or groups of symptoms (such as from gastro-oesophageal reflux disease and irritable bowel syndrome) 
may co-exist with postprandial distress syndrome. 
Diagnostic criteria for epigastric pain syndrome 
Must include at least one of the following symptoms at least 1 day a week:
1. Bothersome epigastric pain (that is, severe enough to impact on usual activities)
2. Bothersome epigastric burning (that is, severe enough to impact on usual activities)
Supportive criteria 
1. Pain may be induced by ingestion of a meal, may be relieved by ingestion of a meal, or may occur while fasting; 2. postprandial 
epigastric bloating, belching, and nausea can also be present; 3. persistent vomiting likely suggests another disorder;  
4. heartburn is not a dyspeptic symptom but may often co-exist; 5. the pain does not fulfil biliary pain criteria; 6. symptoms 
that are relieved by evacuation of faeces or gas generally should not be considered part of dyspepsia; 7. other digestive symptoms 
(such as from gastro-oesophageal reflux disease and irritable bowel syndrome) may co-exist with epigastric pain syndrome.
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present in a lower percentage of patients1. Impaired gastric relax-
ation in response to food (that is, impaired accommodation) has 
also been found in about one third of patients with FD1. Hyper-
sensitivity to mechanical stimulation (for example, distention) 
of the stomach or the small bowel (or both) is frequent, and 
affected patients may also show hypersensitivity to chemi-
cal stimuli such as acid and lipids1. Acute infection is known 
to trigger so-called “post-infectious FD” in at least 10–20% of 
individuals1. The diagnosis of “Helicobacter pylori-associated dys-
pepsia” can be made if successful eradication leads to long-term 
resolution of symptoms1. A relationship between the gut and 
psyche has been described in this condition because patients with 
psychological disease (that is, anxiety or depression) are at increased 
risk of developing FD, and vice versa1. Many of these factors can 
impact on mucosal integrity and duodenal permeability, effects that 
have been related to the activation of the innate mucosal immune 
system. Experimental evidence provides some insight into this 
complex mechanism in humans. Psychological stress mediated by 
corticotrophin-releasing hormone has been shown to alter intestinal 
permeability through a mast cell–dependent mechanism5. Recent 
research has also shown differences in the duodenal microbiome 
between patients with FD and controls, although it remains uncer-
tain whether this represents “cause or effect”.
Studies have also evaluated whether the two FD subgroups— 
PDS and EPS—differ with regard to pathophysiological mecha-
nisms. The results suggest that PDS is associated with gastric 
hypersensitivity, delayed gastric emptying, anxiety, and the pres-
ence of increased intra-epithelial eosinophils in the duodenum 
and other evidence of an activated mucosal immune system6–9. 
Additionally, PDS presents frequently “as an overlap syndrome” 
with other functional GI disorders (for example, irritable bowel 
syndrome, or IBS)10. In contrast, patients with EPS have little 
evidence of abnormal GI motility and function. EPS may be associ-
ated with the presence of other centrally mediated pain syndromes 
(for example, fibromyalgia)11.
Diagnosis
The diagnosis of FD is based on clinical assessment and exclu-
sion of organic disease. Thus, before the diagnosis of FD is made, 
laboratory tests and upper GI endoscopy with biopsies are 
normally performed to exclude infection (in particular, H. pylori), 
peptic ulceration, celiac disease, and neoplasia1. Physiological 
investigations are normally not required at this stage1.
Differential diagnosis
Gastro-oesophageal reflux disease (GERD) is a potential cause 
of “dyspeptic symptoms” that is highly prevalent in the commu-
nity. GERD is present when the reflux of stomach contents causes 
symptoms or mucosal disease (or both) and is characterized by the 
presence of heartburn and regurgitation. Formally, if heartburn is 
present, then this excludes the diagnosis of FD in the Rome IV 
classification12. However, studies show that reflux and dyspeptic 
symptoms co-exist in up to 40% of cases, which is much more 
often than expected by chance13–15. This overlap between GERD 
and FD is not surprising given the immediate proximity and 
shared innervation of the oesophagus and proximal stomach.
Rome IV divides patients with GERD into those with erosive 
reflux disease (ERD), non-ERD (NERD, pathological acid expo-
sure), reflux hypersensitivity (RH, normal acid exposure but 
association between reflux and symptoms), and functional heart-
burn (FH, no association between reflux and symptoms)12. FD 
overlaps with ERD, NERD, RH, and FH with increasing fre-
quency. Patients with FH have more frequent PDS symptoms, 
whereas patients with NERD have more EPS symptoms (typically, 
epigastric burning)15,16. Conversely, pathological acid exposure 
is present in about one third of patients with a clinical diagnosis 
of FD and in at least half of the subgroup with epigastric burn-
ing, which also more frequently responds to proton pump inhibi-
tor (PPI) therapy17. Not only oesophageal but also duodenal acid 
exposure has been linked to EPS. Acid exposure of the duodenum 
is also associated with duodenal infiltration with inflammatory 
cells in patients with FD18. Mucosal acid exposure is a possible 
mechanism in duodenal permeability, predisposing to duodenal 
inflammation and altered sensitivity19. These observations may 
well explain why a proportion of FD patients without GERD 
respond to acid suppression. It is clear that several pathologies can 
cause symptoms, and conversely it is very likely that the overlap 
between the two functional conditions is the result of the shared 
pathophysiological mechanisms (for example, hypersensitiv-
ity) playing a role in two different regions of the GI tract. If the 
diagnosis remains uncertain after a trial of acid suppression, then 
manometry and ambulatory pH-impedance studies provide an 
objective assessment of oesophageal acid exposure and the asso-
ciation between reflux and patient symptoms12. Additionally, 
these tests can identify dysmotility (for example, oesophageal 
spasm) that can present with similar symptoms and behavioural 
conditions (for example, rumination syndrome) that are frequently 
triggered by dyspeptic symptoms12.
FD can also overlap with chronic nausea and vomiting disor-
ders. According to Rome IV criteria, these disorders include 
chronic nausea and vomiting syndrome (CNVS), cyclic vomiting 
syndrome (CVS), and cannabinoid hyperemesis syndrome 
(CHS)1. CNVS is characterized by the presence of bothersome 
(that is, severe enough to impact on usual activities) nausea, 
occurring at least 1 day per week and/or one or more vomiting 
episodes per week in the absence of an organic explanation of 
symptoms or of self-induced vomiting, eating disorders, 
regurgitation, or rumination. CVS is characterized by stereotypical 
episodes of vomiting regarding onset (acute) and duration 
(less than 1 week) with at least three discrete episodes in the prior 
year and two episodes in the past 6 months, occurring at least 
1 week apart in the absence of vomiting between episodes. 
CHS is characterized by episodes resembling CVS in terms 
of onset, duration, and frequency; presents after prolonged 
excessive cannabis use; and is relieved by sustained cessation 
of cannabis use. These disorders have been, in general, poorly 
studied, and it is possible that they overlap with other functional 
disorders. Given the current knowledge about these disorders, it 
is necessary to identify patients with nausea or vomiting (or both) 
as prevalent symptoms, as these patients are more difficult to 
manage in clinical practice and  probably should be referred to 
specialized centres.
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IBS is a frequent functional disorder with a prevalence of about 
10% in the general population. Rome IV defines the condition in 
terms of the presence of chronic recurrence of pain in associa-
tion with defaecation and/or an altered bowel habit in terms of 
either stool frequency or stool consistency20. An important overlap 
is present between FD and IBS with both occurring in 30% and 
60% of patients, respectively10. Overlap may be more common 
in patients with severe symptoms than in patients with mild 
symptoms and in PDS than in EPS, especially in patients with 
postprandial fullness10,21,22. Moreover, longitudinal studies 
demonstrate that the risk of a patient with FD developing IBS 
is increased by up to eightfold compared with the general 
population23. These findings have led many to question whether 
these conditions are truly distinct or share common pathogenic 
mechanisms. Indeed, the pathophysiological mechanisms shared 
by PDS and IBS are very similar and include anxiety, altered 
motility, and visceral hypersensitivity. Low-grade inflamma-
tion with activation of the innate mucosal immune system and 
increased mucosal permeability has also been documented in 
both conditions19.
Management
The management of patients with FD should start with reassur-
ance and education about the possible pathophysiological and risk 
factors associated with FD appropriate for the PDS or EPS 
subgroup or both1. Lifestyle and dietary recommendations may be 
helpful1,24. Avoidance of non-steroidal anti-inflammatory drugs, 
coffee, high-fat foods, alcohol, and smoking is commonly recom-
mended on the basis of physiological studies and case reports; 
however, the real value of these recommendations is unclear1,24.
The next step recommended by the Rome committee is to exclude 
iatrogenic causes of dyspeptic symptoms and to recognize and 
treat overlapping disease. Identification of H. pylori infection 
is appropriate, as prospective trials indicate that eradication 
therapy is curative in approximately 1 in 10 infected patients1. If 
the patient is not infected, then an empirical trial of acid sup-
pression is justified to suppress symptoms related to an atypical 
presentation with GERD1. Individuals with overlap IBS may 
respond to spasmolytics and stool regulation.
Pharmacological treatments for FD that are more effective than 
placebo in randomized controlled trials and are available in the 
market are limited1,24. These include acid suppression (PPIs), H2 
receptor antagonists (H2RAs), prokinetics, herbal preparations, 
and antidepressants1,24. Dietary interventions and medications 
that modulate digestive function may be more likely to be effec-
tive in PDS patients in whom abnormal gastric function is present1. 
Conversely, pain modulators and, if appropriate, antidepressants 
may be most appropriate in EPS1. This hypothesis is (indirectly) 
supported by the observation that the presence of normal gastric 
emptying on scintigraphy in patients with FD is associated with a 
good response to low-dose antidepressant medications that target 
visceral hypersensitivity (see below).
Acid and reflux suppression
A just-published Cochrane systematic review has concluded that 
PPIs are effective for the treatment of FD, independent of the 
dose and duration of treatment compared with placebo. PPIs may 
be slightly more effective than H2RAs for the treatment of FD, 
even if the evidence is scarce25. A recent randomized, placebo- 
controlled trial with an alginate-antacid preparation (Gaviscon) 
that controls both acid and non-acid reflux has also shown a sig-
nificant benefit not only in typical reflux but also in dyspeptic 
(epigastric pain) symptoms26,27. It is uncertain what proportion 
of patients who respond to acid and reflux suppression have an 
atypical presentation of GERD.
Prokinetics
Historical studies with cisapride, a mixed 5-HT4 agonist and 
5-HT3 antagonist with procholinergic effects, indicate that 
selected prokinetics can be more effective than placebo in treat-
ing FD24. Unfortunately, this medication is now restricted in 
most countries because of increased risk of tachyarrhythmia in 
patients with heart disease24. Only limited data are present for 
the dopamine-2 antagonists domperidone and metoclopramide 
although they are prescribed extensively24. However, owing to 
cardiac and neurological side effects, the use of these medica-
tions for long-term treatment is not recommended. One phase IIb 
randomized, placebo-controlled study reported that itopride, 
a dopamine D2 antagonist and acetylcholinesterase inhibitor, 
is effective in FD, in particular for the management of pain and 
fullness24. However, two subsequent phase III trials were 
negative24. Whether this was related to the selection of different 
patient populations in the original Japanese and the subsequent 
US trials remains uncertain. More recent data have demon-
strated that acotiamide at a dose of 100 mg three times daily was 
efficacious and safe in the treatment of PDS28–30. The drug has been 
commercially available in Japan since 2013, and trials in Europe 
and the USA are in progress28. Interestingly, a higher percentage 
of patients with PDS have been reported to respond to the treat-
ments with acotiamide. It may be that this is related to effects 
on gastric motility and gastric emptying documented in animal 
models28. Data have also recently appeared about the possible 
effect of prucalopride, a 5-HT4 agonist licensed in Europe and 
Canada for the treatment of refractory constipation, in treat-
ing FD. This drug increases oesophageal and gastric motility in 
healthy subjects31, and recent data, still in abstract form, have also 
reported a benefit in treating symptoms of patients with FD and 
gastroparesis32. Iberogast (STW5), a nine-herb combination, has 
been shown in studies to relax the gastric fundus, promote gastric 
emptying, and reduce visceral sensitivity through multiple puta-
tive mechanisms1. Some clinical data also support its use, and it 
is a popular over-the-counter remedy for FD in several European 
countries. However, a recent report of severe hepatotoxicity lead-
ing to liver transplantation potentially associated with the use of 
Iberogast suggests some caution in prescribing this medication33. 
Finally, rikkunshito, another herbal medicine, which is thought to 
accelerate gastric emptying, has been shown to improve symptoms 
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of epigastric pain and postprandial fullness in patients with FD 
in a randomized clinical trial34.
Centrally acting drugs
A substantial body of work supports the use of low-dose anti-
depressants in the management of FD and other functional GI 
disorders and chronic pain syndromes35. Talley et al.36 recently 
conducted an important randomized controlled trial that com-
pared the effects of two classes of antidepressant in FD: (i) the 
tricyclic amitriptyline (50 mg) and (ii) the selective serotonin 
reuptake inhibitor (SSRI) escitalopram (10 mg). A large number 
(n = 292) of patients with Rome II dysmotility-like (similar to 
PDS) or ulcer-like (similar to EPS) FD were studied. Solid gas-
tric emptying was documented by gastric scintigraphy, and the 
maximally tolerated ingestion of liquid nutrient was documented 
to estimate gastric accommodation and sensation36. Significant 
treatment effects were observed over 12 weeks. Amitriptyline, but 
not escitalopram, appeared to benefit patients with FD, particu-
larly those with ulcer-like FD (EPS-like)36. Interestingly, delayed 
gastric emptying was associated with a poor response to treat-
ment, a finding that supports the hypothesis that clinical presen-
tation and physiological studies can help direct therapy36. These 
findings are consistent with the Nortriptyline for Idiopathic 
Gastroparesis (NORIG) study, which randomly assigned 130 
patients with idiopathic gastroparesis to nortriptyline (a tricyclic 
antidepressant) or placebo for 15 weeks (91% of patients met 
diagnostic criteria for PDS)37. In this study, active treatment was 
not superior to placebo in treating patients; however, the majority 
(86%) had gastroparesis on scintigraphy37. Importantly, the trial by 
Talley et al. found that, although adverse events were commonly 
reported, there was no difference in side effects among the placebo, 
amitriptyline, and escitalopram, except in neurological symptoms 
with the SSRI36. These findings support the use of amitriptyline in 
FD patients without delayed gastric emptying. A course of therapy 
without documenting gastric emptying can be justified, as these 
medications are generally well tolerated at low doses.
A just-published meta-analysis concluded that certain neurolep-
tics, like levosulpiride, have prokinetic actions and are more 
effective than placebo in patients with FD in secondary or tertiary 
care35. However, it remains uncertain whether other psychotropic 
drugs, including 5-HT1A receptor agonists, tetracyclic antidepres-
sants, or serotonin-norepinephrine reuptake inhibitors (SNRIs), 
are effective treatments in FD35. In the case of 5-HT1A agonists, 
although there have been three trials, each used a different drug 
(sumatriptan, buspirone, and tandospirone), and the results were 
conflicting35. These medications are of particular interest because, 
in addition to their anxiolytic and antidepressant effects, both 
relax the gastric fundus and reduce gastric sensitivity (key patho-
logical mechanisms in PDS). Trials reported reduced symptoms of 
postprandial fullness, early satiation, and upper abdominal bloat-
ing in randomized, placebo-controlled trials35. Unfortunately, 
although these medications are helpful in some individuals, seda-
tive side effects limit their use in others. In the case of tetracyclic 
antidepressants and SNRIs, there has been only one trial of each of 
these drug classes (mirtazapine and venlafaxine)35.
Psychological and other interventions
Controlled trials suggest clinical benefit of psychological inter-
ventions from several, small randomized controlled studies38; 
however, the quality of evidence is still suboptimal. A recent sys-
tematic review concluded that acupuncture therapy achieves a 
statistically significant effect for FD in comparison with sham 
acupuncture and is superior to medication (prokinetic agents) in 
improving the symptoms and quality of life of patients with FD39. 
Nonetheless, despite stringent methodological analyses, there is 
still need for additional randomized controlled studies of higher 
quality39.
Is this information from the literature of any 
relevance for an evidence-based approach in our 
clinical practice?
The authors of the present review work as clinical gastroen-
terologists with a specialist research interest in functional GI 
disorders and with experience in different European countries. 
They consider that the recent literature provides information that 
can inform and hopefully improve clinical practice. Table 2 and 
Figure 1, respectively, report the pharmacological options and the 
practical management algorithm in FD.
Whenever we consider the primary, secondary, or tertiary setting, 
it is of key importance to recognize the typical presentation of 
patients with FD. The Rome criteria are not primarily intended for 
use in clinical practice; however, it can be helpful to use symp-
tom-based criteria to establish a “positive” diagnosis of this condi-
tion. This aids communication with the patient. At the same time, 
the criteria can help to differentiate FD from other conditions (for 
example, GERD alone, IBS alone, or chronic nausea and vomit-
ing disorders). If alarm symptoms are present, then these should be 
investigated (even if there is a high suspicion of functional disease). 
If they are absent, then endoscopy is not mandatory at the initial 
presentation and non-invasive investigation is recommended to 
test for the presence of H. pylori and, if present, to eradicate it, 
regardless of the presence of different subgroups of patients with 
FD. Resolution of symptoms after eradication should be reassessed 
in a few months. In patients with a negative test for H. pylori or 
without resolution of symptoms after eradication, the symptoms of 
FD should be carefully evaluated to identify those with EPS, PDS, 
and overlap, which according to the recent publication should be 
considered PDS3.
EPS should be treated with acid suppressants. If PPI therapy is 
not effective, then some patients may benefit more from H2RAs24. 
An alternative (or supplementary) therapy is the addition of 
an alginate preparation, recently re-evaluated and found to be 
effective in the treatment of GERD26.
In patients with EPS, if a trial of acid and reflux suppression fails, 
then tricyclic antidepressants, such as amitriptyline, should be con-
sidered. In clinical practice, we start with slow increasing of the 
dose (normally amitriptyline 25 mg one quarter daily for 1 week, 
then one half daily for another week, and finally one daily until 
the next consultation in about 2 months), informing the patient 
Page 6 of 13
F1000Research 2017, 6(F1000 Faculty Rev):1778 Last updated: 28 SEP 2017
about possible delayed benefit and early minor side effects (that is, 
dry mouth). We find this approach useful to minimize side effects 
and improve compliance. Moreover, a follow-up consultation at 
about 2 months reinforces the patient’s motivation to continue the 
treatment.
In contrast, in patients with PDS, prokinetic therapy may improve 
symptoms. However, as summarized above, the market does not 
offer much choice. Taken on an as-required basis, domperidone 
or metoclopramide is a reasonable first choice for this patient 
group; however, long-term treatment is no longer recommended. 
The authors of the present review have obtained good clinical 
responses applying prucalopride in some patients with FD, as 
recently suggested by the literature. Starting with half the licenced 
dose for constipation (prucalopride 1 mg daily) and building up 
to 2 mg daily if tolerated is a useful addition, in particular in FD 
patients with overlapping constipation. In PDS patients who fail 
to respond, treatment with an antidepressant is the next step; how-
ever, it may be reasonable to check gastric emptying prior to start-
ing treatment because the treatment response appears to be poor if 
delayed gastric emptying is present36. In severe cases, especially 
those with weight loss, mirtazapine can be a good choice since it 
also relaxes the stomach and promotes weight gain40. Given the 
frequent association with anxiety, if this is considered a likely 
driver of symptoms, then treatment with SSRIs is reasonable, even 
though no data support this approach in FD patients per se. 
Certainly, anxiety and depression have been shown to impact on 
gastric motor and sensory function41.
In patients who do not respond to empirical treatment, further 
functional evaluations are normally advocated to select appro-
priate management1. However, many of these investigations are 
available in highly specialized referral centres or used primarily 
for research purposes or both42. The electronic barostat is consid-
ered the gold standard to assess gastric accommodation and vis-
ceral sensitivity, but the technique is invasive and is mainly used for 
research, and recent studies have suggested that the barostat bag 
could influence the gastric motor response42. New, less invasive 
techniques are in evaluation to replace the barostat. The nutrient 
drink test has been proposed as an alternative. In this test, a defined 
nutrient meal is ingested over a period of time until dyspeptic 
symptoms develop or the patient reports feeling full42. Response to 
treatment can be measured by repeating the test42. More recently, 
intragastric pressure measurement during a nutrient meal change 
was proposed as a minimally invasive test of nutrient tolerance and 
accommodation in FD42. However, the test needs further validation42. 
Gastric scintigraphy is the reference test of gastric emptying and 
is clinically more widely accessible than tests of accommoda-
tion43. Methodology has been extensively validated; however, 
unfortunately, standard test meals are not widely applied43. In most 
centres, only the gastric emptying of solids is evaluated43. If gastric 
emptying is delayed, then the diagnosis of “gastroparesis” is made; 
Table 2. Pharmacological treatment options for functional dyspepsia.
Acid suppression 
Proton pump inhibitors (standard dose should be enough) 
H2 receptor antagonists (less effective acid suppression than proton pump inhibitors; however, anti-histamine effects may be 
beneficial in some patients with functional dyspepsia)
Prokinetic  
Metoclopramide (limited evidence and not recommended for long-term treatment because of neurological side effects) 
Domperidone (limited evidence and not recommended for long-term treatment because of potential cardiac arrhythmias) 
Prucalopride (evidence based on one study published as abstract) 
Acotiamide (evidence based on two phase III studies, currently available only in Japan)
Centrally acting drugs  
Tricyclic antidepressants (for example, low-dose amitriptyline 25 mg daily, thought to reduce visceral hypersensitivity and 
reduce functional pain) 
Selective serotonin reuptake inhibitors (for example, paroxetine, primarily targeting co-existing anxiety and depression) 
Neuroleptics (for example, levosulpiride also has prokinetic effects) 
5-HT1 agonists (that is, buspirone, tandospirone anxiolytics that may also improve early satiety and postprandial distress) 
Noradrenergic and specific serotonergic antidepressants (for example, mirtazapine has anxiolytic effects and may also relax 
the gastric fundus, reduce early satiety, and improve appetite)
Herbal preparations  
Iberogast (no prescription required, may have prokinetic effects on gastric emptying with improvement in reflux and dyspeptic 
symptoms) 
Rikkunshito (may have prokinetic effects and improve dyspeptic symptoms)
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Figure 1. Practical management algorithm in functional dyspepsia. EPS, epigastric pain syndrome; FD, functional dyspepsia; 
FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; GERD, gastro-oesophageal reflux disease; GI, 
gastrointestinal; IBS, irritable bowel syndrome; PDS, postprandial distress syndrome; SSRI, selective serotonin reuptake inhibitor; TCA, 
tricyclic antidepressant.
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however, unless the delay is severe (for example, three times the 
upper limit of normal), there is only a weak association between 
this finding and patient symptoms or disease severity44. Moreover, 
it is not clear that the finding of gastroparesis predicts positive 
outcome for prokinetic medication44. Conversely, the diagnosis 
of gastric dumping has implications for dietary and pharmaco-
logical therapy44. It is interesting to note that patients with rapid 
gastric emptying (that is, dumping) can present with symptoms 
identical to those of gastroparesis and this may be the strongest 
reason to do the test44.
However, the reality is that after performing tests, at this time, not 
so many specific pharmacological therapies are available to cor-
rect abnormal physiology1. Nevertheless, there is evidence that a 
clear explanation for symptoms improves patient acceptance of dis-
ease and reduces out-patient attendance45. Otherwise, an intensified 
medical management involving psychological intervention could 
be applied, as this has been reported to give superior long-term 
outcomes46.
At present, the information obtained from gastric emptying stud-
ies is limited. For example, gastric scintigraphy studies often 
provide only a single measurement of gastric emptying of a solid 
meal. As already suggested43, it is unlikely that this captures the 
complexity of GI function (Figure 2). In particular, a single sum-
mary outcome measurement, normalized after ingestion of a 
meal, misses the “early gastric emptying” that occurs even dur-
ing meal ingestion47. Moreover, the current way of performing 
the gastric emptying test does not incorporate the report of sen-
sations experienced during meal ingestion47. A new development 
in this field is the combination of a nutrient drink test with gas-
tric scintigraphy to obtain a comprehensive assessment of gastric 
motor and sensory function47. Assessment of the scintigraphic 
images after ingestion of the relatively large (400 mL) “Notting-
ham Test Meal” provides an evaluation of gastric accommoda-
tion and sensitivity in addition to gastric emptying47. The test uses 
standard technology, and normal values of this test have been 
published48. Ongoing studies will disclose whether this test can 
predict the response to pharmacological treatments in clinical 
practice.
Conclusions
The literature of these last five years concerning FD has 
provided some relevant information for clinical practice. It has 
indeed confirmed the importance of correctly recognizing the 
different symptoms affecting the patient in order to identify 
PDS or EPS. This classification indeed seems to correspond to 
different pathophysiological mechanisms and treatments. 
Figure 2. Abnormal gastric motility and function could be implicated in the pathophysiology of symptoms in functional dyspepsia, 
especially in patients with postprandial distress syndrome. Heightened visceral sensitivity has an important role in epigastric pain 
syndrome but is also present in many individuals with postprandial distress. In clinical practice, with the exception of detection of abnormal 
gastric emptying by scintigraphy, it is currently not possible to identify the specific causes of disease.
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However, it also reveals that we urgently need new tests to bet-
ter study the GI function of these patients in order to develop 
effective treatments and better understand the pathophysiological 
mechanisms to target.
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